Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-blind, Sham-controlled Study for Assessing the Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes (ReCET Study)

NCT06267391 is registered in ClinicalTrials.gov with Endogenex, Inc. as lead sponsor.

NCT NCT06267391
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06267391 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-blind, Sham-controlled Study for Assessing the Safety and Effectiveness of Endoscopic Intestinal Re-Cellularization Therapy in Individuals With Type II Diabetes (ReCET Study)
Lead sponsor
Endogenex, Inc.
Phase
Not applicable
Overall status
Active, not recruiting
Start date
May 1, 2024
Completion date
October 1, 2027
Enrollment
350 (actual)
Sites
44

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes, diabetes mellitus, type 2, type 2 diabetes, type 2 diabetes mellitus, type2diabetes